| 영문 | anaphylaxis | 한글 | 아나필락시스, 과민증 |
|---|---|---|---|
| 설명 | 아나필락시스라는 말은 제 1형 과민반응과 같은 말로 외계의 물질에 대한 면역 반응이 지나치게 항진되어 있는 병적인 상태를 말한다. 면역이란 외부물질에 대한 방어를 목적으로 하는 세포들의 활동을 의미하며, 여기에는 항체의 형성, 세포들의 포식작용(외부에서 들어온 물질을 면역기능을 하는 세포가 잡아먹는 것)등이 포함된다. 항체의 형성은 외부로부터 들어온 물질을 우선 큰포식세포 등이 포식을 하고 이것에 대한 정보를 T-림프구에게 전달하고 T-림프구는 이 정보를 처리하여 집약된 정보를 B-림프구에게 전달하며 이 세포로 하여금 그 물질 에 대한 항체를 생성하게 한다. 항체는 외부의 물질과 정확히 결합하여 외부의 물질의 활성화를 없애는 물질이다. 이렇게 형성된 항체중에서 IgE에 부착될 수 있는, 즉 이미 항체 IgE가 형성된(이렇게 되기 위해서는 그 물질이 이전에 한 번 몸속에 들어 왔어야 한다) 물질이 히스타민 등의 여러 물질이 나오게 되고 이런 물질들에 의해서 생기는 여러 가지 신체에 해로운 반응이 생겨난다. 그래서 필요 이상으로 과민한 이러한 형태의 면역작용을 거치는 반응을 아니필락시스라 한다. |
||
| SRS-A | Slow Reacting Substance of Anaphylaxis |
|---|---|
| ASA | acetylsalicylic acid; active systemic anaphylaxis; Adams-Stokes attack; American Society of Anesthes... |
| BK-A | basophil kallikrein of anaphylaxis |
| ECFA, ECF-A | eosinophilic chemotactic factor of anaphylaxis |
| PAF-A | platelet-activating factor of anaphylaxis |
| ACA | Active cutaneous anaphylaxis |
|---|---|
| IA | Idiopathic Anaphylaxis |
| PCA | Passive Cutaneous Anaphylaxis |
| SRS-A | Slow Reacting Substance of Anaphylaxis |
| ASA | active systemic anaphylaxis |
| antireticular cytotoxic serum | An antiserum specific for cells of the reticuloendothelial system. (05 Mar 2000) |
|---|---|
| cytotoxic | <pharmacology> Chemicals that are directly toxic to cells, preventing their reproduction or growth. Cytotoxic agents can, as a side effect, damage healthy, noncancerous tissues or organs which have a high proportion of actively dividing cells, for example, bone marrow, hair follicles. These side effects limit the amount and frequency of drug administration. (16 Dec 1997) |
| cytotoxic cell | Cells of the immune system that inhibit or help to terminate an immune response, e.g., suppressor macrophages and suppressor T-cells. Synonym: cytotoxic cell. (05 Mar 2000) |
| cytotoxic drugs | <pharmacology> Anti-cancer drugs which act by killing or preventing the division of cells. See: chemotherapy. (13 Nov 1997) |
| cytotoxic reaction | An immunologic (allergic) reaction in which noncytotropic IgG or IgM antibody combines with specific antigen on cell surfaces; the resulting complex initiates the activation of complement which causes cell lysis or other damage, or which, in the absence of complement, may lead to phagocytosis or may enhance T lymphocyte involvement. (05 Mar 2000) |
| cytotoxic T-cell | <haematology, immunology> Subset of T lymphocytes (mostly CD8) responsible for lysing target cells and for killing virus infected cells (in the context of Class I histocompatibility antigens). (18 Nov 1997) |
| cytotoxic t-lymphocyte | A type of CD8 or, less often, CD4 lymphocyte that kills diseased cells infected by a specific virus or other intracellular microbe. CTLs interact with MHC class I receptors (see Major Histocompatibility Complex). On infected cells and have the prime role in cellmediated immunity (see). Cytovene: See: Ganciclovir. (09 Oct 1997) |
| cytotoxic T lymphocyte-specific serine protease | <enzyme> Structural sequence given in first source Registry number: EC 3.4.21.- Synonym: cytotoxic t lymphocyte-specific serine protease ccp I, cytotoxic t lymphocyte specific serine protease ccp II, mast cell protease type II (26 Jun 1999) |
| T cytotoxic cells | Lymphocyte-like effector cells which mediate antibody-dependent cell cytotoxicity. They kill antibody-coated target cells which they bind with their fc receptors. (12 Dec 1998) |
| T-lymphocytes, cytotoxic | Immunised T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (mlc), in vivo during a graft-versus-host (gvh) reaction, or after immunization with an allograft, tumour cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (cml). These cells are distinct from natural killer cells (killer cells, natural) and from killer cells mediating antibody-dependent cell cytotoxicity. (12 Dec 1998) |
| active anaphylaxis | Reaction following inoculation of antigen in a subject previously sensitised to the specific antigen, in contrast to passive anaphylaxis. (05 Mar 2000) |
| aggregate anaphylaxis | <pharmacology> As opposed to prophylaxis. A system or treatment that leads to damaging effects on the organism. <immunology> Now reserved for those inflammatory reactions resulting from combination of a soluble antigen with IgE bound to a mast cell that leads to degranulation of the mast cell and release of histamine and histamine like substances, causing localised or global immune reponses. Results in an acute allergic reaction with shortness of breath, rash, wheezing, hypotension. See: hypersensitivity. (18 Nov 1997) |
| anaphylaxis | <pharmacology> As opposed to prophylaxis. A system or treatment that leads to damaging effects on the organism. <immunology> Now reserved for those inflammatory reactions resulting from combination of a soluble antigen with IgE bound to a mast cell that leads to degranulation of the mast cell and release of histamine and histamine like substances, causing localised or global immune reponses. Results in an acute allergic reaction with shortness of breath, rash, wheezing, hypotension. See: hypersensitivity. (18 Nov 1997) |
| antiserum anaphylaxis | A reaction resulting from inoculation of antigen in an animal previously inoculated intravenously with specific antiserum from another animal, a latent period being required between the two inoculations. Synonym: antiserum anaphylaxis. (05 Mar 2000) |
| generalised anaphylaxis | The immediate response, involving smooth muscles and capillaries throughout the body of a sensitised individual, that follows intravenous (and occasionally intracutaneous) injection of antigen (allergen). See: anaphylactic shock. Synonym: systemic anaphylaxis. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|